Although 1 in 1000 lymphoma diagnoses occurs in pregnancy, literature on best practices for treatment in this patient group is limited.
Tazemetostat yielded clinically meaningful, durable responses and was well tolerated in patients with relapsed or refractory follicular lymphoma.
Responses were also observed in patients previously treated with HDAC or mTOR inhibitors.
Combined modality therapy for early-stage favorable HL yielded excellent outcomes and limited excess radiation doses to organs at risk.
The expanded approval was based on data from the randomized, open-label, phase 3 KEYNOTE-204 trial.
Findings suggest that brentuximab vedotin plus nivolumab was well tolerated and active in older patients with previously untreated HL with comorbidities.
A case report detailed reinfection with SARS-CoV-2 in an immunocompromised patient with Waldenström macroglobulinemia.
Pregnant patients with non-Hodgkin lymphoma may be able to receive CHOP-like chemotherapy during pregnancy with some risks.
In a phase 2 trial, obinutuzumab added to induction therapy showed promising activity and tolerability for transplant-eligible mantle cell lymphoma.
Investigators characterized the risks of stage- and cause-specific mortality among patients with classical Hodgkin lymphoma treated with chemotherapy.
Among a subset of patients with previously treated Waldenström macroglobulinemia, ibrutinib is highly active and may lead to long-term disease control.
The signaling pathways detected may shed light on new treatment strategies.
Investigators assessed safety and efficacy outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
In Japan, insurance coverage for breast implantation is limited to procedures using Allergen-manufactured products.
Characterizing gene expression profiles of FL cells from intrafollicular and extrafollicular regions may help to identify future therapeutic targets.
Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.
Delayed evaluation could decrease unnecessary invasive tests.
Using a grading system for skin flare reactions increases potential for continuing administration of mogamulizumab despite the occurrence of this adverse effect.
Investigators measured ixazomib, dexamethasone, and rituximab combination treatment among patients with treatment-naive Waldenström macroglobulinemia.
Researchers assessed diagnosis, risk-stratification, and management of 3 distinct subgroups of primary cutaneous lymphomas.
Novel immunotherapies and small molecule pathway inhibitors are transforming the standard of care for some of the most challenging lymphoma subtypes.
A small study suggests that low-dose pembrolizumab or nivolumab may be effective and safe for the treatment of r/r classical Hodgkin lymphoma.
Neurotoxicity is a common AE associated with CAR-T administration, but there are limited data characterizing it among patients with LBCL who received axi-cel.
Lipid changes in the B-cell lymphoma microenvironment may influence natural killer cell metabolism and function.
In this study, researchers determined that the quantity and quality of discussions regarding survivorship and late effects of treatment between AYA lymphoma survivors and their oncologists is improving, but survivorship information is still lacking.
While the rate of certain HIV-linked non-Hodgkin lymphomas has declined since the introduction of ART, the incidence of Burkitt lymphoma has remained steady.
Researchers studied clinical characteristics linked to overall survival and lymphoma-specific survival in patients with plasmablastic lymphoma.
Researchers evaluated data from younger patients with Waldenström macroglobulinemia to determine features that predict outcomes in this patient population.
The treatment reduced hospital stay but not neutropenia duration or infection rate.
All responders were found to have the same structural rearrangements.
Researchers at UT MD Anderson Cancer Center in Houston present tools that support patient adherence to acalabrutinb in the setting of MCL.
TP53 missense mutations through routine analysis is needed for patients with mantle cell lymphoma.
Study results suggest allogeneic SCT as standard consolidation therapy in pediatric patients with progression during frontline therapy or relapse of a CD3-positive ALCL.
Researchers in the Netherlands conducted HOVON-84 to determine what benefit, if any, early rituximab intensification had in adult patients with untreated DLBCL.
Among patients with T cell lymphoblastic leukemia, event-free survival at 24 months is a strong surrogate endpoint for long-term survival.
The overall response rate was 95.9%, with 100% of patients in the TN group and 93.9% of patients in the RR group responding.
Tafasitamab-cxix is a humanized Fc-modified monoclonal antibody that targets CD19 antigen on the surface of pre-B and mature B lymphocytes and on several B-cell malignancies, including DLBCL.
CD30 CAR-T cell treatment after lymphodepletion may produce antitumor activity without significant toxicity in relapsed or refractory Hodgkin lymphoma.
Researchers for the RELEVANCE study measured MRD in a subset of patients to compare the molecular response of patients receiving R2 vs R-chemo.
The FDA has granted accelerated approval to Tecartus™ (brexucabtagene autoleucel; Kite Pharma) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
A prospective NCTN PET-directed analysis aimed to eradicate the short- and long-term toxicities associated with RT in patients with limited-stage DLBCL.
Researchers studied the pros and cons of transplantation from different donor sources to enhance overall outcomes of allo-HSCT in adults with T-cell malignancies.
A retrospective study found similar efficacy and toxicity outcomes among patients with refractory DLBCL who were treated with axi-cel outside of trial inclusion criteria.
The authors noted that these findings should be seen as a reference for the mutational landscape in MCL at baseline and at disease progression after treatment.
Researchers examine how far follicular lymphoma treatment has come, what limitations still remain, and where the management of the disease is headed.
Because primary pancreatic lymphoma is a rare disease, optimal diagnostic and therapeutic protocols have not yet been established.
A clinical trial suggests efficacy and a manageable adverse event profile with selinexor for the treatment of relapsed or refractory DLBCL.
Flow cytometry may provide an efficient, sensitive, and specific tool for the differential diagnosis of breast implant–associated ALCL, but a cell block may be able to answer additional questions about the disease.
AALL0434, one of the largest prospective studies of T-LL, resulted in successful disease-free and overall survival outcomes.
For pediatric high-risk B-cell NHL, adding rituximab to standard LMB chemotherapy prolongs event-free and overall survival but may increase adverse events.
The FDA has granted accelerated approval of Xpovio® (selinexor; Karyopharm) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.